Piqray: German Withdrawal, European Reimbursement Deals & Broader Indication Plans
Novartis Is Persevering To Make Piqray A Big Player
Executive Summary
Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.
You may also be interested in...
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.
New Pricing Deals Pave Way For Piqray & Trodelvy Reimbursement In England
Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.
NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.